| Literature DB >> 29296228 |
Hao-Zhe Huang1, Guang-Zhi Wang1, Li-Chao Xu1, Guo-Dong Li1, Ying Wang1, Yao-Hui Wang1, Xin-Hong He1, Wen-Tao Li1.
Abstract
The optimal screening or treatment strategies of solitary pulmonary nodules especially ground-glass opacities (GGOs) remain controversial. With CT-guided Hookwire localization, it is accurate to find the small lesions during video-assisted thoracoscopic surgery (VATS). In this study, we evaluate the efficiency and safety of CT-guided Hookwire localization of GGO-dominant (GGO component > 50%) pulmonary nodules before VATS and investigate the correlation between the radiologic features and pathology. From April 2008 to April 2014, a total of 273 patients with solitary GGO-dominant pulmonary nodules were included. Tumor size was 12.4 ± 5.7 mm in diameter, including 208 pulmonary adenocarcinomas and 65 benign nodules. Dislodgement occurred in six patients (2.20%) during surgery. Postoperative complications included asymptomatic needle track hemorrhage (27.1%), minimal pneumothorax (5.9%) and hemoptysis (0.4%). In 208 (76.2%) pulmonary adenocarcinomas, 82 nodules showed ≥90% GGO and 126 showed 50%≤GGO<90%, while 84 nodules staged as T1aN0M0, 96 staged as T1bN0M0, and 28 staged as T1cN0M0. The multivariable analysis demonstrated that 50%≤GGO<90% (HR=2.459, 95% CI: 1.246-4.853, P=0.010), speculation (HR=3.911, 95% CI: 1.966-7.663, P<0.001), lobulation (HR=4.582, 95% CI: 2.149-9.767, P<0.001) and vascular convergence (HR=4.096, 95% CI: 1.132-14.824, P=0.032) were the independent risk factors to identification of the malignant GGO-dominant pulmonary nodules. In conclusions,CT-guided Hookwire localizati for GGO-dominant pulmonary nodules before VATS is a safe and effective procedure for accurate diagnosis and resection of indeterminate solitary pulmonary nodules.Entities:
Keywords: Hookwire localization; ground-glass opacities; pulmonary nodules; radiological feature; video-assisted thoracoscopic surgery
Year: 2017 PMID: 29296228 PMCID: PMC5746130 DOI: 10.18632/oncotarget.22551
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
The clinical characteristics of patients (n=273)
| Characteristic | N (%) |
|---|---|
| Age, years | 53.9±10.6 (27-80) |
| ≥70 | 18 (6.59) |
| <70 | 255 (93.41) |
| Gender | |
| Male | 91 (33.33) |
| Female | 182 (66.67) |
| Smoking history | |
| Yes | 216 (79.12) |
| No | 57 (20.88) |
| Tumor size | |
| >6mm | 16 (5.86) |
| 6-8mm | 47 (17.22) |
| <8mm | 210 (76.92) |
| Histologic types | |
| Benign | 65 (23.81) |
| AAH | 23 (8.42) |
| Inflammatory cell infiltration | 19 (6.96) |
| Hyperplasia of fibrous tissue | 15 (5.49) |
| Granulomas | 5 (1.83) |
| Hamartomas | 3 (1.10) |
| Malignant | 208 (76.19) |
| AIS | 130 (47.62) |
| MIA | 23 (8.42) |
| IA | 55 (20.15) |
| Increased serum tumor marker | |
| CEA | 4 (1.47) |
| CYFRA 21-1 | 58 (21.25) |
CEA: carcinoembryonic antigen; CYFRA 21-1: cytokeratin 19 fragments, AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma.
Characteristics of Hookwire localization
| Characteristics | Value |
|---|---|
| Duration (min) | 8.3±3.2 (2.5-23.0) |
| Insertion (mm) | 78.4±15.8 (44.3-134.2) |
| Relation of Hookwire and GGOs | |
| Through the nodules | 147 (53.8%) |
| Within surrounding 10 mm range | 126 (46.2%) |
| Complications | |
| Needle track hemorrhage | 74 (27.1%) |
| Minimal pneumothorax | 16 (5.9%) |
| Hemoptysis | 1 (0.4%) |
GGO: ground glass opacity.
GGO component and Stage of lung cancer in different pathologies (n)
| Subject | AIS | MIA | IA | Total |
|---|---|---|---|---|
| GGO omponent | ||||
| GGO≥90% | 63 (30.29) | 10 (4.81) | 9 (4.33) | 82 (39.42) |
| 50%≤GGO<90% | 67 (32.21) | 13 (6.25) | 46 (22.12) | 126 (60.58) |
| Stage | ||||
| T1aN0M0 | 72 (34.62) | 7 (3.37) | 5 (2.40) | 84 (40.38) |
| T1bN0M0 | 55 (26.44) | 12 (5.77) | 29 (13.94) | 96 (46.15) |
| T1cN0M0 | 3 (1.44) | 4 (1.92) | 21 (10.10) | 28 (13.46) |
AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma.
Percentage of GGO component in different TNM stages of lung cancer (n)
| TNM stage | GGO≥90% | 50%≤GGO<90% | N |
|---|---|---|---|
| T1aN0M0 | 41 (19.71) | 43 (20.67) | 84 |
| T1bN0M0 | 36 (17.31) | 60 (28.85) | 96 |
| T1cN0M0 | 5 (2.40) | 23 (11.06) | 28 |
| N | 82 | 126 | 208 |
The radiologic and clinicopathologic features of 273 GGOs
| Characteristics | Malignant (%) | Benign (%) | Total | OR | 95% CI | |
|---|---|---|---|---|---|---|
| Age (years) | 54.5±10.3 | 51.9±11.4 | 1.024 | 0.997~1.051 | 0.082 | |
| ≥70 | 15 (7.21) | 3 (4.62) | 18 | |||
| <70 | 193 (92.79) | 62 (95.38) | 255 | |||
| Gender | 1.345 | 0.754~2.399 | 0.316 | |||
| Female | 142 (68.27) | 40 (61.54) | 182 | |||
| Male | 66 (31.73) | 25 (38.46) | 91 | |||
| Smoking history | 0.994 | 0.969~1.019 | 0.616 | |||
| Yes | 42 (20.19) | 15 (23.08) | 57 | |||
| No | 166 (79.81) | 50 (76.92) | 216 | |||
| CEA (ng/ml) | 2.00±1.51 | 1.81±1.23 | 1.172 | 0.929 ~1.478 | 0.180 | |
| >5.2 | 3 (1.44) | 1 (1.54) | 4 | |||
| ≤5.2 | 205 (98.56) | 64 (98.46) | 269 | |||
| CYFRA21-1 (ng/ml) | 2.74±1.44 | 2.58±1.28 | 1.145 | 0.924 ~1.420 | 0.216 | |
| >3.3 | 46 (22.12) | 12 (18.46) | 58 | |||
| ≤3.3 | 162 (77.88) | 53 (81.54) | 215 | |||
| Tumor location | 0.395 | |||||
| RUL | 84 (40.38) | 28 (43.08) | 112 | 1.800 | 0.71~4.564 | 0.216 |
| RML | 13 (6.25) | 2 (3.08) | 15 | 3.900 | 0.711~21.406 | 0.117 |
| RLL | 38 (18.27) | 12 (18.46) | 50 | 1.900 | 0.664~5.434 | 0.231 |
| LUL | 58 (27.88) | 14 (21.54) | 72 | 2.486 | 0.904~6.836 | 0.078 |
| LLL | 15 (7.21) | 9 (13.85) | 24 | |||
| Tumor size (mm) | 12.89±5.71 | 10.70±4.92 | 0.047 | |||
| >6mm | 8 (3.85) | 8 (12.31) | 16 | 0.273 | 0.097~0.767 | 0.014 |
| 6-8mm | 35 (16.83) | 12 (18.46) | 47 | 0.795 | 0.382~1.657 | 0.541 |
| <8mm | 165 (79.33) | 45 (69.23) | 210 | |||
| GGO component | () | () | 0.356 | 0.200~0.636 | <0.001 | |
| ≥90% | 82 (39.42) | 42 (64.62) | 124 | |||
| 50%-90% | 126 (60.58) | 23 (35.38) | 149 | |||
| Margin | 0.344 | 0.167~0.708 | 0.004 | |||
| Irregular | 187 (89.9) | 49 (75.38) | 236 | |||
| Regular | 21 (10.1) | 16 (24.62) | 37 | |||
| Spiculation | 6.926 | 3.748~12.801 | <0.001 | |||
| Yes | 157 (75.48) | 20 (30.77) | 177 | |||
| No | 51 (24.52) | 45 (69.23) | 96 | |||
| Lobulation | 8.418 | 4.291~16.513 | <0.001 | |||
| Yes | 141 (67.79) | 13 (20) | 154 | |||
| No | 67 (32.21) | 52 (80) | 119 | |||
| bubble-like lucency | 4.018 | 1.819~8.873 | <0.001 | |||
| Yes | 75 (36.06) | 8 (12.31) | 83 | |||
| No | 133 (63.94) | 57 (87.69) | 190 | |||
| Calcification | 0.302 | 0.060~1.536 | 0.149 | |||
| Yes | 3 (1.44) | 3 (4.62) | 6 | |||
| No | 205 (98.56) | 62 (95.38) | 267 | |||
| Pleural retraction | 1.213 | 0.640~2.299 | 0.555 | |||
| Yes | 59 (28.37) | 16 (24.62) | 75 | |||
| No | 149 (71.63) | 49 (75.38) | 198 | |||
| Vascular convergence | 12.656 | 3.843~41.685 | <0.001 | |||
| Yes | 79 (37.98) | 3 (4.62) | 82 | |||
| No | 129 (62.02) | 62 (95.38) | 191 |
Malignant (n=208), Benign (n=65). CEA: serum carcinoembryonic antigen, CYFRA 21–1: cytokeratin 19 fragments; RUL= Right upper lobe, RML = Right middle lobe, RLL = Right lower lobe, LUL = Left upper lobe, LLL = Left lower lobe.
Figure 1Flowchart of patient identification and inclusion
Figure 2Hookwire system and the relative complications of localization
(A) Hookwire system (Pajunk GmbH Medizintechnologie, Germany); (B) Hookwire has anchored the lesion; (C&D) Minimal pneumothorax and needle track hemorrhage.
Figure 3Resection of pGGO under VATS
(A) A right lateral approach VATS view of the right upper lung. (B) The wedge resection directly guided by Hookwire with no obviously visible subpleural lesion.